Medical Devices and Technologies
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities.
Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.
Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.
For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.
Our clients in the medical devices sector include Biomet, Samsung, GE Healthcare, Johnson & Johnson, Fresenius, Covidien, St Jude Medical and Novartis.
News & insights
Blog Post: 13 JANUARY 2020
The Digital Healthcare Act (Digitale-Versorgung-Gesetz DVG) was published in the German Federal Law Gazette (Bundesgesetzblatt) on 18 December 2019 and entered into force on 19 December 2019, having…Read more
Blog Post: 03 JANUARY 2020
At a time of heightened regulatory and market uncertainty, it’s perhaps surprising to see life sciences and healthcare sector M&A continuing to grow so strongly. Indeed, with deal value up by more…Read more
Blog Post: 27 NOVEMBER 2019
The Medical Devices Regulation, the “MDR”, which comes largely into force in May 2020, will introduce significant changes to the way in which software used in a medical context will be regulated in…Read more
Blog Post: 22 NOVEMBER 2019
In August 2019, the Slovak government introduced a draft law which suggested removing CBD (cannabidiol) from the list of psychotropic substances. The draft law therefore attempted to make CBD a…Read more